ABSTRACT
The determination of gender in wild animals is essential for behavioural and ecological studies, and also for conservation. The objectives of this study were (i) the determination of gender in faecal samples of Iberian wolf based on the differential concentrations of sexual steroid hormones (SSH) and (ii) to analyse the profiles of SSH in males and females (considering the gender determination carried out previously) during the non-reproductive and reproductive periods. The quantification of androgens (testosterone, T), progestin (progesterone, P) and oestrogen (oestradiol, E) was conducted by means of enzyme immunoassay. The k-means conglomerate analysis showed that the 59 faecal samples grouped into three different conglomerates, considering SSH levels. Groups 1 and 2 showed higher levels of T than group 3. Therefore, the faecal samples included in groups 1 and 2 (17 samples) corresponded to males and those of group 3 (42 samples) to females. The levels of T + P + E and T/P were higher in the group of males than in the group of females. The results of this study also showed that levels of T in males were higher during the reproductive period than in the non-reproductive period. However, the concentrations of P and E turned out to be higher during the non-reproductive season. In females, the levels of the three hormones (T, P and E) were higher during the reproductive period.
Subject(s)
Feces/chemistry , Gonadal Steroid Hormones/analysis , Reproduction/physiology , Sex Determination Analysis/veterinary , Wolves , Animals , Biomarkers/analysis , Estradiol/analysis , Estradiol/blood , Female , Immunoenzyme Techniques/veterinary , Male , Pregnancy , Progesterone/analysis , Progesterone/blood , Sex Determination Analysis/methods , Species Specificity , Testosterone/analysis , Testosterone/blood , Wolves/blood , Wolves/metabolism , Wolves/physiologyABSTRACT
This is a retrospective study to evaluate the history of hepatocellular carcinoma and find the relationship between clinical, biochemical and ultrasonographic features and survival in Italian patients. In 135 consecutive patients median follow-up was 16 months (range 1-66 months) and median survival from the time of diagnosis was 12 months. Univariate analysis showed that individual variables associated with significantly decreased survival included: absence of therapy, Okuda's Stage III, Child-Pugh's Class C, alpha-fetoprotein greater than 400 ng/ml, presence of symptoms, moderate or severe ascites, tumor involving both lobes, mixed internal echo pattern, and multinodular or massive type. Multiple regression analysis (Cox model) revealed that the mixed internal echo pattern of hepatocellular carcinoma, the presence of moderate or severe ascites and Okuda's Stage III were independent predictors of high risk of death. These data can help in selecting patients whose probability of survival is considered high enough to undergo treatment and may be useful for stratifying patients in randomized controlled trials.
Subject(s)
Carcinoma, Hepatocellular/mortality , Liver Neoplasms/mortality , Adult , Aged , Aged, 80 and over , Carcinoma, Hepatocellular/blood , Carcinoma, Hepatocellular/diagnosis , Follow-Up Studies , Humans , Italy/epidemiology , Liver Neoplasms/blood , Liver Neoplasms/diagnosis , Middle Aged , Neoplasm Staging , Prognosis , Regression Analysis , Retrospective Studies , Survival RateABSTRACT
Bleeding from oesophageal or gastric varices is a major complication of portal hypertension, and a leading cause of death in patients with liver cirrhosis. The efficacy of oral beta-blockers in preventing recurrence of gastrointestinal haemorrhage in these patients is debatable. A recent meta-analysis showed benefits in reducing bleeding risk, but results on mortality were inconclusive. We combined results from all available randomized controlled trials to evaluate treatment with beta-blockers in the prevention of the first bleeding episode, or recurrent haemorrhage, in patients with cirrhosis and varices. Scrutiny of the data from all 13 available randomized trials, in which 1154 patients were entered, suggests that treatment (4 trials, 589 patients) may decrease the rate of the first bleeding episode (p less than 0.001), but not of death in the same patients. Results from the analysis of 9 trials (565 patients) for the prevention of recurrent haemorrhage suggest a beneficial effect of treatment on bleeding (p less than 0.0001), and a slight efficacy on survival (p less than 0.05) by the DerSimonian and Laird method. The implications of this analysis are that (i) updating of meta-analyses is useful to overcome the problem of negative results of undersized trials and previous meta-analyses; and (ii) treatment with beta-blockers, for the prevention of the first bleeding episode or recurrent haemorrhage, appears to be promising, but its effects on an important end point, such as death, still need to be reliably assessed.
Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Esophageal and Gastric Varices/complications , Gastrointestinal Hemorrhage/prevention & control , Liver Cirrhosis/complications , Humans , Meta-Analysis as Topic , Randomized Controlled Trials as TopicABSTRACT
Hepatocellular carcinoma (HCC) is the most frequent cancer of the liver and, worldwide, is the seventh most common tumor in males and the ninth in females; the annual incidence is estimated to be 1,000,000 cases newly diagnosed, with a male to female ratio of 4:1. The incidence of HCC is Italy is 6.9 cases for males and 2.7 for females as for the regions with intermediate risk for this tumor. During the last ten years many epidemiological studies, case-control and cohort, have associated HCC to hepatitis B virus (HBV) infection establishing that among HBsAg carriers the relative risk of HCC is between 10 and 20 to demonstrate the strength of the association. In addition to HBV infection, cirrhosis, aflatoxins, alcohol, tobacco smoking and oral contraceptives have been evaluated as risk factors for HCC. The importance of the contribution of these risk factors to the development of HCC and the perspectives for prevention in different geographical areas will be discussed.
Subject(s)
Carcinoma, Hepatocellular/epidemiology , Liver Neoplasms/epidemiology , Aflatoxins/toxicity , Africa/epidemiology , Asia/epidemiology , Carcinoma, Hepatocellular/etiology , Cohort Studies , Europe/epidemiology , Female , Hepatitis B/complications , Humans , Italy/epidemiology , Liver Cirrhosis/complications , Liver Neoplasms/etiology , Male , Risk Factors , Sex FactorsABSTRACT
Cases are reported of two patients in whom acute hepatitis and cholestatic jaundice were induced by a tricyclic antidepressant, amineptine. A 29-year old woman received amineptine for 10 days before the onset of acute hepatitis. Slight jaundice and pruritus were preceded by fever, nausea and anorexia. The case is documented by a rapid return to normality of the liver function tests after amineptine was discontinued. We also report the case of a 55-year old woman to whom amineptine was administered for 4 weeks: she was admitted to our Department due to a 14-day history of pruritus and painless jaundice. Histological examination, in this case showed marked cholestasis without inflammatory infiltration. After suspending the treatment, it took 3 weeks for the liver function tests to return to normal. These observations, and the features of the cases published in the literature, suggest that amineptine can produce a wide spectrum of liver injuries, in different patients, taking the form of hepatocellular necrosis, cholestasis or a combination of both.